Baxter International (BAX) Set to Announce Earnings on Thursday

Baxter International (NYSE:BAXGet Rating) is scheduled to post its quarterly earnings results before the market opens on Thursday, July 28th. Analysts expect Baxter International to post earnings of $0.88 per share for the quarter. Baxter International has set its Q2 guidance at $0.86-0.89 EPS and its FY22 guidance at $4.12-4.20 EPS.Individual interested in registering for the company’s earnings conference call can do so using this link.

Baxter International (NYSE:BAXGet Rating) last posted its quarterly earnings data on Thursday, April 28th. The medical instruments supplier reported $0.93 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $0.13. The business had revenue of $3.71 billion during the quarter, compared to the consensus estimate of $3.68 billion. Baxter International had a return on equity of 21.59% and a net margin of 7.80%. Baxter International’s quarterly revenue was up 25.8% on a year-over-year basis. During the same period last year, the company earned $0.76 earnings per share. On average, analysts expect Baxter International to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Baxter International Stock Up 0.4 %

NYSE:BAX opened at $65.59 on Thursday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 1.45 and a current ratio of 2.10. The company has a market cap of $33.03 billion, a PE ratio of 31.38, a PEG ratio of 1.24 and a beta of 0.68. Baxter International has a 52-week low of $62.70 and a 52-week high of $89.70. The stock has a 50-day simple moving average of $69.07 and a 200 day simple moving average of $76.83.

Baxter International Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 3rd. Investors of record on Friday, September 2nd will be issued a dividend of $0.29 per share. The ex-dividend date of this dividend is Thursday, September 1st. This represents a $1.16 dividend on an annualized basis and a dividend yield of 1.77%. Baxter International’s payout ratio is presently 55.50%.

Institutional Trading of Baxter International

Several hedge funds have recently added to or reduced their stakes in BAX. Ancora Advisors LLC lifted its holdings in Baxter International by 29.2% during the 1st quarter. Ancora Advisors LLC now owns 1,351 shares of the medical instruments supplier’s stock worth $114,000 after purchasing an additional 305 shares during the last quarter. Eudaimonia Partners LLC bought a new position in Baxter International during the 1st quarter worth $340,000. KB Financial Partners LLC increased its stake in Baxter International by 6.2% during the 1st quarter. KB Financial Partners LLC now owns 4,815 shares of the medical instruments supplier’s stock worth $373,000 after acquiring an additional 279 shares during the period. Zions Bancorporation N.A. increased its stake in Baxter International by 30.1% during the 1st quarter. Zions Bancorporation N.A. now owns 10,964 shares of the medical instruments supplier’s stock worth $850,000 after acquiring an additional 2,535 shares during the period. Finally, Gabelli Funds LLC increased its stake in Baxter International by 6.0% during the 1st quarter. Gabelli Funds LLC now owns 281,374 shares of the medical instruments supplier’s stock worth $21,818,000 after acquiring an additional 15,925 shares during the period. 86.65% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts recently commented on BAX shares. Raymond James reduced their price target on Baxter International from $96.00 to $85.00 in a research report on Friday, April 29th. The Goldman Sachs Group cut Baxter International from a “neutral” rating to a “sell” rating and reduced their price target for the company from $88.00 to $77.00 in a research report on Monday, April 4th. Wells Fargo & Company cut Baxter International from an “overweight” rating to an “equal weight” rating and set a $71.00 price target for the company. in a research report on Friday, June 24th. Citigroup reduced their price target on Baxter International from $98.00 to $85.00 and set a “buy” rating for the company in a research report on Tuesday, May 17th. Finally, Stifel Nicolaus reduced their price target on Baxter International from $85.00 to $75.00 in a research report on Monday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $86.38.

About Baxter International

(Get Rating)

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit.

Recommended Stories

Earnings History for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.